QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: mol.108.046201v1 74/3/654    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasinski, A. L. Articles by Fu, H. Search for Related Content PubMed PubMed Citation Articles by Kasinski, A. L. Articles by Fu, H.

Inhibition of IB Kinase-Nuclear Factor-B Signaling Pathway by 3,5-Bis(2-flurobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin

Graduate Programs in Genetics and Molecular Biology (A.L.K.) and Molecular and Systems Pharmacology (S.L.T.), Departments of Pharmacology (Y.D., J.Z., H.F.), Hematology and Oncology (S.-Y.S., F.R.K., M.S.), and Chemistry (A.S., J.P.S., D.L.), and Emory Chemical Biology Discovery Center (Y.D., A.S., J.P.S., D.L., H.F.), Emory University, Atlanta, Georgia; and Division of Oral Biology and Medicine, University of California Los Angeles Dentistry, Los Angeles, California (C.-Y.W.)

Received for publication February 10, 2008.

Accepted for publication June 23, 2008.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The nuclear factor-B (NF-B) signaling pathway has been targeted for therapeutic applications in a variety of human diseases, includuing cancer. Many naturally occurring substances, including curcumin, have been investigated for their actions on the NF-B pathway because of their significant therapeutic potential and safety profile. A synthetic monoketone compound termed 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24) was developed from curcumin and exhibited potent anticancer activity. Here, we report a mechanism by which EF24 potently suppresses the NF-B signaling pathway through direct action on IB kinase (IKK). We demonstrate that 1) EF24 induces death of lung, breast, ovarian, and cervical cancer cells, with a potency about 10 times higher than that of curcumin; 2) EF24 rapidly blocks the nuclear translocation of NF-B, with an IC₅₀ value of 1.3 µM compared with curcumin, with an IC₅₀ value of 13 µM; 3) EF24 effectively inhibits tumor necrosis factor (TNF)--induced IB phosphorylation and degradation, suggesting a role of this compound in targeting IKK; and 4) EF24 indeed directly inhibits the catalytic activity of IKK in an in vitro-reconstituted system. Our study identifies IKK as an effective target for EF24 and provides a molecular explanation for a superior activity of EF24 over curcumin. The effective inhibition of TNF--induced NF-B signaling by EF24 extends the therapeutic application of EF24 to other NF-B-dependent diseases, including inflammatory diseases such as rheumatoid arthritis.

View larger version (19K): [in this window] [in a new window]   Fig. 1. Structures of curcumin and its analog EF24.

NF-B is maintained in an inactive state in the cytoplasm by the inhibitor of B(IB), which masks the nuclear localization signal of NF-B. Phosphorylation of IB by the inhibitor of B kinase (IKK), via the canonical NF-B pathway, results in subsequent ubiquitination of IB and proteasomal degradation. It is this degradation of IB that liberates NF-B, allowing its localization to the nucleus and the transcriptional activation of its target genes. In contrast, aberrant activation of NF-B contributes to deregulated growth, resistance to apoptosis, and propensity to metastasize observed in many cancers (Rayet and Gélinas, 1999; Richmond, 2002). The NF-B effect is in part due to the up-regulation of NF-B-controlled genes that promote survival function of tumor cells, including c-myc, Bcl-xL, and members of inhibitor of apoptosis family of genes. In addition, many anticancer agents can induce the activation of NF-B, resulting in reduced therapeutic efficacy (Nakanishi and Toi, 2005). Thus, agents that effectively impair the NF-B pathway are expected to have significant therapeutic potential.

In this report, we identify the molecular mechanism of action of EF24. We show that treatment with EF24 results in a marked decrease in cellular viability. The dose necessary to reduce viability correlates well with that needed for EF24 to impair the nuclear translocation of NF-B and to inhibit IKK. EF24 is at least 10 times more potent than curcumin and represents a lead compound for further therapeutic development of a new generation of natural product-derived anticancer agents.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials Curcumin was purchased from Alfa Aesar (Ward Hill, MA), and its structural analog, EF24, was prepared as reported previously (Adams et al., 2004). Both compounds were dissolved in DMSO, with a stock concentration of 10 mM. TNF- (Sigma-Aldrich, St. Louis, MO) was resuspended in water to a final concentration of 10 µg/ml. Glutathione transferase (GST)-IB (1-54) was purified from expression plasmid as described previously (Mercurio et al., 1997). Antibodies against pS32-IB and IB were purchased from Cell Signaling Technology Inc. (Danvers, MA). Antibodies against IKK and IKKβ were purchased from Imgenex (San Diego, CA). Antibodies to Raf-1, and secondary antibody conjugates horseradish peroxidase goat anti-mouse and horseradish peroxidase-goat anti-rabbit antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Cell Cultures Cells were maintained in either in RPMI 1640 medium (A549, H157, H460, Calu-1, H358, PC3, 1A9, and MDA-MB231) or Dulbecco's modified Eagle's medium (HeLa), with 10% fetal bovine serum and penicillin/streptomycin in a 37°C incubator with 5% CO₂. For Western blot analysis, unless otherwise noted, cells were lysed in 1% NP-40 lysis buffer (1% Nonidet P40, 10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM NaF, 2 mM Na₃VO₄, 5 mM Na₄P₂O₇, 10 µg/ml aprotonin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride).

Cytotoxicity Assay Cells were plated at 5000 cells/well in 96-well plates. They were treated with test agents in triplicate on the following day and further incubated for 48 h before viability assay was carried out. The sulforhodamine B assay was performed to evaluate cell viability and to obtain the IC₅₀ values (Rubinstein et al., 1990; Skehan et al., 1990). It measures cellular protein content to determine cell density. The mean value and standard error for each treatment were determined, and the cell viability index relative to control (untreated) was calculated. The IC₅₀ is defined as the concentration of agents that decrease viability by 50% in a total cell population (cell viability index, 0.5) compared with control cells (cell viability index, 1) at the end of the incubation period.

High Content Analysis of NF-B Subcellular Translocation A549 cells were plated in 96-well plates (BD Biosciences Discovery Labware, Bedford, MA) at 10,000 cells/90 µl/well and grown for 20 h. Test compounds were added to each well and incubated at 37°C. All samples were performed in triplicates. The cells were stimulated with TNF- as indicated. Reactions were terminated by washing the plates with ice-cold phosphate-buffered saline (PBS) followed by fixation with paraformaldehyde (2%; 100 µl) for 30 min at room temperature. Cells were permeabilized with Triton X-100 (0.1%; 100 µl) for 20 min, washed three times with PBS, and blocked with bovine serum albumin (1%; 100 µl) for 1 h. Rabbit anti-p65 NF-B antibody (Santa Cruz biotechnology, Inc.) was added and incubated overnight at 4°C. Cells were washed three times in PBS and incubated with goat anti-rabbit IgG with conjugated Alexa Fluor 488 (50 µl; Invitrogen, Carlsbad, CA) along with Hoechst 33342 (1 µg/ml; Promega, Madison, WI). After washing with PBS, cells were imaged with the ImageXpress 5000 with the filter set for fluorescein isothiocyanate (excitation at 490 nm, emission at 525 nm, with dichroic mirror at 505 nm) and 4,6-diamidino-2-phenylindole (excitation at 350 nm, emission at 479 nm, with dichroic mirror at 400 nm) (Molecular Devices, Sunnyvale, CA).

View larger version (44K): [in this window] [in a new window]   Fig. 2. EF24 shows more potent cytotoxic effect than curcumin on cancer cells. Cells were grown in 96-well plates and were treated with EF24 or curcumin as indicated for 48 h. Cell viability was assessed by the sulforhodamine B method and expressed as percentage of control (DMSO). Results with a panel of lung cancer cells are shown in a: A549, H358 (lung adenocarcinoma); H460 (large cell carcinoma); H157 (squamous cell carcinoma); and Calu-1 (lung epidermoid carcinoma). b, results with breast (MDA-MB231), cervical (HeLa), prostate (PC3), and ovarian (1A9) cancer cell lines.

Western Blotting Cells were lysed in NP-40 buffer (1.0% NP-40, 10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM NaF, 2 mM Na₃VO₄, 5 mM Na₄P₂O₇, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride). Equal volumes of cell lysate were subject to electrophoresis on 12.5% SDS-PAGE. Proteins were then electrotransferred to a nitrocellulose membrane (GE Water and Process Technologies, Trevose, PA) as described previously (Zhang et al., 1999). Membranes were blocked in a solution of 5% nonfat dry milk in Tris-buffered saline-Tween 20 buffer (20 mM Tris, pH 7.6, 500 mM NaCl, and 0.5% Tween 20) for 30 min followed by incubation with primary antibody for at least 2 h. The membrane was then washed and treated with the corresponding horseradish peroxidase-conjugated anti-mouse Ig or anti-rabbit Ig as indicated. Immunodetection was performed using West Pico (Pierce Chemical, Rockford, IL) or West Dura (Pierce Chemical) followed by imaging on an Image Station 2000R (Eastman Kodak, Rochester, NY).

Immunoprecipitation Cells were seeded in 150-mm plates to approximately 70% confluence 1 day before treatment. Cells were treated with increasing doses of EF24 or curcumin with or without TNF- as indicated and lysed in 1% NP-40 lysis buffer at 4°C. Lysates were clarified by centrifugation (14,000 rpm; 10 min; 4°C). Cytoplasmic extracts were immunoprecipitated with an anti-IKK antibody (Imgenex) at 4°C overnight. Protein G-Sepharose beads (50% slurry; Pfizer, New York, NY) in lysis buffer were added to each reaction the following day and incubated for an additional 2 h. Protein G beads were then gently spun down and washed two times with NP-40 lysis buffer and one final time with the kinase assay buffer (50 mM HEPES, pH 7.4, 20 mM MgCl₂, and 2 mM dithiothreitol). The immunocomplexes were used for IKK kinase assays.

Kinase Assays IKK Immunocomplex Assay. Immunoprecipitated complexes were added to kinase reaction buffer containing [-³²P]ATP (20 µCi with 10 µM unlabeled ATP) and GST-IB (residues 1-54; 5 µg) in a total volume of 25 µl and incubated at 30°C for 30 min. Reactions were stopped by boiling the kinase solution in a 6x SDS sample buffer for 5 min. The samples were resolved on 12.5% SDS-PAGE. The top portion of the gel was transferred and immunoblotted with anti-IKKβ antibody, whereas the bottom portion was stained with 0.05% Coomassie Blue dye. Radiolabeled phosphate incorporation into GST-IB was assessed by the PhosphorImager and quantified with the ImageQuant software (GE Healthcare).

In Vitro Recombinant IKKβ Assay. Activated recombinant IKKβ in MOPS buffer (8 mM MOPS-NaOH, pH 7.0, 200 µM EDTA, and 15 mM MgCl₂) (Millipore, Billerica, MA) was used to assess the direct effect of EF24 or curcumin on the kinase. The test compounds were incubated in the presence of 40 ng of IKKβ for 15 min at room temperature. The addition of Mg-ATP cocktail (15 mM MgCl₂, 100 µM ATP, 8 mM MOPS-NaOH, pH 7.0, 5 mM β-glycerophosphate, 1 mM EGTA, 200 nM sodium orthovanadate, and 200 nM dithiothreitol), 5 µg of purified GST-IB, and 0.5 µCi of [-³²P]ATP in a final volume of 25 µl started the reaction, which was allowed to proceed at 30°C for 15 min. Reactions were terminated and processed as described under IKK immunocomplex assay. In addition, the radiolabeled GST-IBa protein bands were excised for quantification with a scintillation counter (Beckman LS 6500; Beckman Coulter, Fullerton, CA). For competition assays, total ATP was varied, while the ratio of [-³²P]ATP to nonradioactive ATP remained constant in the reaction. Test compounds and ATP were incubated in the presence of 20 ng of IKKβ at room temperature. At various time points within the linear range of the enzyme, the reaction was terminated by spotting assay mixture (5 µl) onto P81 phosphocellulose paper (Whatman, Maidstone, UK). The filters were washed three times with 0.75% phosphoric acid and once with acetone. Radioactivity was determined by liquid scintillation counting.

	Results

Top Abstract Materials and Methods Results Discussion References

 
EF24 Exhibits a More Potent Cytotoxic Effect than Curcumin. To evaluate the potency of EF24 in comparison with its parent compound curcumin, we carried out cell viability tests with the sulforhodamine B assay on a panel of lung cancer cells (Fig. 2). Treatment of cells with both EF24 and curcumin led to a significantly decreased viability. Dose-response studies revealed that the IC₅₀ value of EF24 was in the range of 0.7 to 1.3 µM for various cell lines, as summarized in Table 1 and Fig. 2. In contrast, under the same treatment conditions, the IC₅₀ value for curcumin ranged from 15 to 20 µM. These data indicate a more potent cytotoxic effect of EF24 over curcumin for lung cancer cells. This study was extended to include ovarian, breast, prostate, and cervical cancer cells. A similar trend was observed with EF24, exhibiting an IC₅₀ value at least 20-fold lower than curcumin for each cell line, respectively, with the exception of PC3 (10-fold lower) (Table 1). These results are consistent with previous reports, and they demonstrate that this monoketone analog of curcumin, EF24, has a much improved cytotoxic activity over the parent compound (Adams et al., 2004, 2005).

High Content Analysis Revealed an Effective EF24 Action in Blocking Nuclear Translocation of NF-B. To understand the mechanism of action of EF24 for its improved bioactivity, we examined its effect on the NF-B signaling pathway, which is suggested to be targeted by curcumin (Singh and Khar, 2006; Lin, 2007). The NF-B transcription factor mediates a critical survival mechanism in lung cancer cells. To monitor the activation status of NF-B, we used a high content analysis (HCA) approach to visualize the dynamic movement of the NF-B p65 subunit between the cytoplasm and nucleus under various experimental conditions. The p65 subunit in A549 cells was detected with an immunofluorescent probe, and its movement was captured through an automated fluorescence microscope (Fig. 3). To validate the HCA assay and to establish experimental conditions for testing the EF24 effect, we initially used a known NF-B activator, TNF-, to manipulate the NF-B movement (Rothe et al., 1995). Although the majority of the p65 subunit was detected in the cytoplasm, the addition of 10 ng/ml TNF- resulted in complete translocation of the p65 protein into the nucleus, as indicated by overlapping p65 green fluorescent signal with 4,6-diamidino-2-phenylindole-stained blue nuclear signal (Fig. 3a). Time course and dose-response experiments were carried out to establish an EC₅₀ value of 1.5 ng/ml TNF-, which was used to set the subsequent experimental conditions (Fig. 3b). To examine whether EF24 has any effect on the NF-B pathway, A549 cells were pretreated with EF24 before TNF- was added to cause predominant nuclear translocation of NF-B. Strikingly, EF24 pretreatment retained the NF-B in the cytoplasm even when the amount of TNF- used completely relocated the p65 subunit to the nucleus. Curcumin showed a similar effect, albeit with much higher concentration to achieve an effect as EF24 (Fig. 3). Quantification of captured images under various experimental conditions led to the establishment of dose-response curves, which gave rise to an IC₅₀ value of 1.3 and 13 µM for EF24 and curcumin, respectively (Fig. 3c). The 10-fold difference in blocking the NF-B translocation activity between EF24 and curcumin as revealed by the quantitative HCA is consistent with their difference in cytotoxicity against lung cancer cells. It is likely that EF24 induces cell death in part through interfering with the NF-B-mediated survival signaling.

View larger version (37K): [in this window] [in a new window]   Fig. 3. EF24 impairs TNF- induced NF-B nuclear translocation. A549 cells were grown in 96-well plates and treated with TNF- or control (DMSO) for 30 min before sample processing for the detection of NF-B as described under Materials and Methods (top two rows of a). The induction of NF-B nuclear translocation by TNF- was quantified as shown in b, with an apparent EC50 value of 1.5 ng/ml. The effect of EF24 or cucumin treatment (30 min) on TNF--induced nuclear translocation of NF-B was shown in the lower two rows in a and quantified as shown in c.

View larger version (30K): [in this window] [in a new window]   Fig. 4. EF24 blocks TNF--induced IB degradation and phosphorylation. a, A549 cells were treated with 10 ng/ml TNF-. Whole cell lysates were prepared at indicated times and analyzed for the phosphorylation state of IB with anti-pS32 antibody via Western blotting (top). Then, antibodies on the membrane were stripped and the membrane reprobed for total IB with antiserum against IB (middle). Raf-1 was used as a control (bottom). b, A549 cells were pretreated for various times with 5 µM EF24, or 5 or 50 µM curcumin before the addition of TNF-. Cells were cultured in the presence of 10 ng/ml TNF- for an additional 20 min, lysed, and analyzed for total IB levels by Western blot (top). Raf-1 was used as a control (bottom). c, A549 cells were pretreated with compounds (EF24 or curcumin) as indicated for 30 min. TNF- was added to induce IB phosphorylation. Cell lysates were prepared after 7 min of treatment and used for probing pS32-IB followed by probing total IB with Western blots. Intensity of cross-reacting material bands on Western blots was estimated with a Kodak imaging system. The phosphorylation levels of IB at S32 are normalized to total IB and expressed relative to control sample with DMSO treatment (d).

Because phosphorylation of IB proceeds its degradation, we next examined the effect of EF24 on TNF--induced phosphorylation of IB. A549 cells were pretreated with EF24 or curcumin for 30 min before the addition of TNF- (10 min). Cells were harvested for probing the status of IB phosphorylation with a phosphor-specific antibody, pS32-IB (Fig. 4c). EF24 inhibited TNF--induced IB phosphorylation in a dose-dependent manner, with an IC₅₀ approximately 10-fold less than that of curcumin (Fig. 4d). These results suggest that EF24 antagonizes the nuclear translocation of NF-B through its inhibitory action on the phosphorylation of IB and its subsequent degradation. In support of a selective role of EF24 in inhibiting the IB kinase signaling, further experiments showed that EF24 is unable to inhibit TNF- induced activation of c-Jun NH₂-terminal kinase and extracellular signal-regulated kinase (Supplemental Fig. S1).

EF24 Directly Inhibits the IKKβ Kinase Activity. Because phosphorylation of IB is catalyzed by IKK in the canonical NF-B signaling pathway, the above-mentioned results imply a more potent EF24 action over curcumin on the IKK protein complex. To examine whether EF24 and curcumin differentially target the cellular IKK complex for effective NF-B inhibition, we monitored the kinase activity of IKK upon compound treatment and compared the efficacy of EF24 and curcumin. A549 cells were pretreated with increasing doses of either a compound or vehicle for 1 h before the addition of 10 ng/ml TNF- for 10 min. Cells were lysed, and heterotrimeric IKK complexes were immunoprecipitated with an antibody to IKK. The kinase activity of the immunoprecipitated IKK complex was determined by its ability to phosphorylate recombinant GST-IB. Although pretreatment of cells with EF24 was able to completely neutralize TNF--activated IKK complex activity, pretreatment with curcumin required a much higher dose to achieve a similar effect (Fig. 5). Although this cell-based immunocomplex kinase assay allows the detection of permeabilized compound effect on intracellular IKK complex activity, it is unable to distinguish a direct effect of compound on a specific kinase from an indirect effect. It is possible that EF24 directly targets the IKKβ activity, a well defined kinase for IB. To test this notion, a reconstituted in vitro kinase assay was used with recombinant IKKβ and other defined components in the reaction. Increasing concentrations of EF24 or curcumin were incubated with active recombinant IKKβ for 15 min before the addition of substrate, GST-IB, and [-³²P]ATP. Incorporation of radiolabeled ³²P to GST-IB was detected by radiography and quantified by scintillation counting of excised GST-IB protein bands (Fig. 6). It is striking that EF24 effectively inhibited the ability of IKKβ to phosphorylate its physiological substrate IB, with an estimated IC₅₀ value of 1.9 µM. Interestingly, EF24 also impaired the autokinase activity of IKKβ with a similar potency (data not shown). These data strongly support a direct role of EF24 in the inhibition of IKKβ. In contrast, curcumin shows a much weaker effect on IKKβ in the in vitro kinase assay, with an apparent IC₅₀ value above 20 µM (Fig. 6). It is clear that the structural change of curcumin to EF24 has drastically enhanced its inhibitory effect on IKKβ catalytic activity. Thus, this in vitro kinase assay with recombinant IKKβ reveals IKKβ as a direct target of EF24.

View larger version (47K): [in this window] [in a new window]   Fig. 5. EF24 inhibits the kinase activity of endogenous IKK complex A549 cells were pretreated with EF24 or curcumin at indicated doses for 1 h followed by 10 ng/ml TNF- stimulation for 10 min. Cell lysates were prepared for immunoprecipitation of the IKK complex with an antibody raised against IKK. The isolated IKK complex was used in an in vitro kinase assay with GST-IB as a substrate. Samples were resolved on a SDS-PAGE and stained for total IB protein with Coomassie Blue (a, middle). The gel was dried to reveal radiolabeled IB with a PhosphorImager (a, top). The amount of IKKβ in the immunocomplex used in each reaction was revealed by Western blot. As a negative control, the inactive IKK complex without TNF- treatment is shown in left lane. Quantified result from a is plotted relative to vehicle control (b).

View larger version (45K): [in this window] [in a new window]   Fig. 6. EF24 inhibits IKKβ kinase activity in a reconstituted system. Recombinant IKKβ was incubated with increasing concentrations of EF24 (a) or curcumin (b) for 15 min. Addition of Mg/[-32P] cocktail with purified GST-IB started the reactions, which were continued for 15 min at 30°C. Proteins were separated by SDS-PAGE and processed for radiolabeled GST-IB (top), total GST-IB (middle), and IKKβ (bottom) as described in legend to Fig. 5. Controls include reactions without IKKβ (lane 1) or without IB (lane 2).

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
The monoketone analog of curcumin, EF24, has been shown to induce cell cycle arrest and apoptosis in many cancer cell lines, with potency much higher than that of curcumin. Consistent with previous reports, EF24 exhibited IC₅₀ values 10 to 20 times lower than that of curcumin in a panel of non-small-cell lung cancer cells with different genetic background as well as in ovarian, cervical, breast, and prostate cancer cells. However, the molecular mechanism underlying the enhanced therapeutic efficacy remains to be defined. Here, we present evidence that supports a direct action of EF24 on the NF-B survival signaling pathway. The amount of EF24 required for suppression of lung cancer A549 cell growth has been correlated with its ability to prevent the nuclear translocation of p65 subunit of NF-B, to block IB phosphorylation and its subsequent degradation, and to inhibit the catalytic activity of the IKK protein complex (Fig. 7). Curcumin, in contrast, exhibited at least 10 times lower potency in all of the above-mentioned assays. Importantly, in an in vitro-reconstituted kinase assay, EF24 has been shown to inhibit the kinase activity of IKKβ. Thus, direct targeting of IKKβ and its mediated survival signaling may partially explain the improved therapeutic potency of EF24 over curcumin.

View larger version (26K): [in this window] [in a new window]   Fig. 7. Working model for the EF24 mode of action. EF24 efficiently blocks the cytokine-induced nuclear translocation of NF-B, which is important for cell survival and inflammation signaling. This EF24 activity is at least in part due to its inhibitory effect on IB degradation and possibly through a direct inhibitory effect on the kinase activity of IKKβ.

Why is EF24 a more effective inhibitor of IKKβ than curcumin? This question cannot be answered definitively in the present work, but a possible explanation can be outlined based on structural differences and the commonly accepted mechanism of kinase inhibition. Curcumin exists in the enol form both in the solid state and in solution (Mague et al., 2004; Payton et al., 2007). In addition, in the crystal lattice, the molecule adopts an extended planar form that spans 19 Å in the longest direction (i.e., H-H). The X-ray structure of EF24, in contrast, depicts a nonplanar molecule with a propeller arrangement of the terminal phenyl rings that incorporates a reasonable degree of flexibility and a long dimension of 15 Å (J. P. Snyder and A. Sun, unpublished). Assuming that both curcumin and EF24 occupy at least partially the ATP binding site of IKKβ kinase as the origin of their inhibition, the shorter and more flexible EF24 would seem to be more adaptable to the globular binding pocket. For comparison, we refer to roscovitine, a compound that potently blocks a number of cyclin-dependent kinases (Meijer and Raymond, 2003). Roscovitine is a nonplanar flexible molecule with a long dimension of 14 Å in a low-energy conformation. The properties match those of EF24 and suggest that a compact and potentially mobile kinase ligand is best suited to the ATP site. The mixed type competitive inhibitor of EF24 with respect to ATP partially supports this notion. Ultimately, this hypothesis can be tested by determination of the X-ray structures of curcumin and EF24 bound to IKKβ.

The NF-B pathway has been found to be activated in lung cancer, with various chemotherapeutic regiments adding to already elevated NF-B activation in tumors and representative cell lines (Mukhopadhyay et al., 1995; Wang et al., 1996). Lung cancer A549 cells may have developed a certain dependence on the up-regulated NF-B pathway for sustained survival. This mechanism may involve up-regulated NF-B-controlled survival genes, such as Bcl-XL and inhibitors of apoptosis. Thus, inhibition of IKKβ and its mediated NF-B signaling by EF24 likely lead to the suppression of survival mechanism and the induction of cell death. In contrast, it has been reported that up-regulated NF-B also has a transcription independent function through suppression of tumor suppressor gene PTEN expression (Vasudevan et al., 2004). Activated p65 in nucleus has been shown to sequester the transcriptional coactivators CBP/p300, leading to the suppression of PTEN expression. PTEN is a negative regulator of Akt, a major survival kinase in A549 cells (Stambolic et al., 1998). In addition to inhibiting NF-B-controlled expression of survival genes, EF24-mediated IKK inhibition may result in the release of p65-sequestered cAMP response element-binding protein-binding protein/p300 and the subsequent activation of PTEN. In support of our model, Selvendiran et al. (2007) demonstrated that EF24 induces the expression of PTEN in ovarian cancer cells, which mediates EF24-triggered G₂/M cell cycle arrest and apoptosis.

Because the IKK protein complex plays a vital role in cellular responses to many environmental signals under both physiological and pathological conditions, IKK inhibitors are known to have significant therapeutic value (Karin, 2006). It is expected that the EF24 class of agents may not only have a role as potential cancer therapeutics but also may have important applications in various IKK/NF-B dysregulated autoimmune and inflammatory diseases, including rheumatoid arthritis.

	Acknowledgements

 
We thank members of the Fu, Khuri, Sun, and Liotta laboratories for assistance and enlightening discussions.

	Footnotes

 
This work was supported in part by National Institutes of Health Grants R01-GM53165 (to H.F.)., P01-CA116676 (to F.R.K., H.F., and S.S.), P50-CA128613 (to S.S., F.R.K., J.P.S., and H.F.), and Emory University Research Committee. F.R.K., S.S., and H.F. are Georgia Cancer Coalition Distinguished Scholars. H.F. is a Georgia Research Alliance Distinguished Investigator. Y.D. is Emory Drug Development and Pharmacogenomics Academy Fellow and recipient of Emory Head and Neck Cancer Specialized Programs of Research Excellence P50-CA128613 career development award. S.L.T. is a recipient of American Association for the Advancement of Science/Packard Fellowship and Emory Facilitating Academic Careers in Engineering and Science program fellow.

ABBREVIATIONS: NF-B, nuclear factor-B; EF24, 3,5-bis(2-flurobenzylidene)piperidin-4-one; IB, inhibitor of B; IKK, inhibitor of B kinase; DMSO, dimethyl sulfoxide; TNF, tumor necrosis factor; NP-40, Nonidet P40; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; GST, glutathione transferase; MOPS, 3-(N-morpholino)propanesulfonic acid; HCA, high content analysis; PTEN, phosphatase with sequence homology to tensin.

The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

Address correspondence to: Dr. Haian Fu, Department of Pharmacology, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322. E-mail: hfu{at}emory.edu

	References

Top Abstract Materials and Methods Results Discussion References

 
Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP, and Shoji M (2005) EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16: 263-275.[CrossRef][Medline]

Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, and Shoji M (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 12: 3871-3883.[CrossRef][Medline]

Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, and Aggarwal BB (2006) Curcumin (diferuloylmethane) downregulates expression of cell proliferation, antiapoptotic and metastatic gene products through suppression of IB kinase and AKT activation. Mol Pharmacol 69: 195-206.[Abstract/Free Full Text]

Anand P, Kunnumakkara AB, Newman RA, and Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818.[CrossRef][Medline]

Beg AA, Finco TS, Nantermet PV, and Baldwin AS Jr (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 13: 3301-3310.[Abstract/Free Full Text]

Bharti AC, Donato N, Singh S, and Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062.[Abstract/Free Full Text]

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, and Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.[Medline]

Commandeur JN and Vermeulen NP (1996) Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 26: 667-680.[Medline]

Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, and Gautam SC (2004) Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 3: 803-812.[Abstract/Free Full Text]

Dhillon N, Wolff RA, Abbruzzese JL, Hong DS, Camacho LH, Li L, Braiteh FS, and Kurzrock R (2006) Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. J Clin Oncol 24 (18 Suppl):Abstract 14151.

Karin M (2006) NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45: 355-361.[CrossRef][Medline]

Levi MS, Borne RF, and Williamson JS (2001) A review of cancer chemopreventive agents. Curr Med Chem 8: 1349-1362.[Medline]

Lin JK (2007) Molecular targets of curcumin. Adv Exp Med Biol 595: 227-243.[Medline]

Mague JT, Alworth WL, and Payton FL (2004) Curcumin and derivatives. Acta Crystallogr C 60: 608-610.

Meijer L and Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36: 417-425.[CrossRef][Medline]

Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, and Rao A (1997) IKK-1 and IKK-2 cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278: 860-866.[Abstract/Free Full Text]

Mukhopadhyay T, Roth JA, and Maxwell SA (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11: 999-1003.[Medline]

Nakanishi C and Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.[CrossRef][Medline]

Osawa T, Sugiyama Y, Inayoshi M, and Kawakishi S (1995) Antioxidative activity of tetrahyrocurcuminids. Biosci Biotechnol Biochem 59: 1609-1612.[Medline]

Payton F, Sandusky P, and Alworth WL (2007) NMR study of the solution structure of curcumin. J Nat Prod 70: 143-146.[CrossRef][Medline]

Rayet B and Gélinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947.[CrossRef][Medline]

Richmond A (2002) Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2: 664-674.[CrossRef][Medline]

Rothe M, Sarma V, Dixit VM, and Goeddel DV (1995) TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 269: 1424-1427.[Abstract/Free Full Text]

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, and Boyd MR (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118.[Abstract/Free Full Text]

Satoskar RR, Shah SJ, and Shenoy SG (1986) Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24: 651-654.[Medline]

Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, and Kuppusamy P (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282: 28609-28618.[Abstract/Free Full Text]

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, and Srinivas PS (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.[Medline]

Singh S and Khar A (2006) Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6: 259-270.[Medline]

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.[Abstract/Free Full Text]

Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, and Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.[CrossRef][Medline]

Vasudevan KM, Gurumurthy S, and Rangnekar VM (2004) Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24: 1007-1021.[Abstract/Free Full Text]

Wang CY, Mayo MW, and Baldwin AS Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787.[Abstract/Free Full Text]

Zhang L, Chen J, and Fu H (1999) Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc Natl Acad Sci U S A 96: 8511-8515.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. Koeberle, H. Northoff, and O. Werz Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1 Mol. Cancer Ther., August 1, 2009; 8(8): 2348 - 2355. [Abstract] [Full Text] [PDF]

				A. Vojdani, J. Lambert, and G. Kellermann The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III Evid. Based Complement. Altern. Med., July 21, 2009; (2009) nep064v1. [Abstract] [Full Text] [PDF]

				A.R.M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin Perspectives for Cancer Prevention With Natural Compounds J. Clin. Oncol., June 1, 2009; 27(16): 2712 - 2725. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: mol.108.046201v1 74/3/654    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasinski, A. L. Articles by Fu, H. Search for Related Content PubMed PubMed Citation Articles by Kasinski, A. L. Articles by Fu, H.